Coherus BioSciences (CHRS) Reports Q3 Loss of $1.79
Get Alerts CHRS Hot Sheet
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.79), versus ($6.23) reported last year. Revenue for the quarter came in at $16.1 million, versus $500 thousand reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
- Universal Health Realty (UHT) Reports Q1 EPS of $0.38
- ChampionX (CHX) Tops Q1 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!